These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 17235304)
1. Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency. Lai JC; Brown BD; Voskresenskiy AM; Vonhoff S; Klussman S; Tan W; Colombini M; Weeratna R; Miller P; Benimetskaya L; Stein CA Mol Ther; 2007 Feb; 15(2):270-8. PubMed ID: 17235304 [TBL] [Abstract][Full Text] [Related]
2. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583 [TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901 [TBL] [Abstract][Full Text] [Related]
4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Loomis R; Carbone R; Reiss M; Lacy J Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752 [TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by G3139 in melanoma cells. Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310 [TBL] [Abstract][Full Text] [Related]
7. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines. Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396 [TBL] [Abstract][Full Text] [Related]
8. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297 [TBL] [Abstract][Full Text] [Related]
9. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Stein CA; Wu S; Voskresenskiy AM; Zhou JF; Shin J; Miller P; Souleimanian N; Benimetskaya L Clin Cancer Res; 2009 Apr; 15(8):2797-807. PubMed ID: 19351753 [TBL] [Abstract][Full Text] [Related]
10. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615 [TBL] [Abstract][Full Text] [Related]
11. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754 [TBL] [Abstract][Full Text] [Related]
12. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045 [TBL] [Abstract][Full Text] [Related]
13. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468 [TBL] [Abstract][Full Text] [Related]
14. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739 [TBL] [Abstract][Full Text] [Related]
15. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Lai JC; Tan W; Benimetskaya L; Miller P; Colombini M; Stein CA Proc Natl Acad Sci U S A; 2006 May; 103(19):7494-9. PubMed ID: 16648253 [TBL] [Abstract][Full Text] [Related]
16. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074 [TBL] [Abstract][Full Text] [Related]
18. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754 [TBL] [Abstract][Full Text] [Related]
19. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589 [TBL] [Abstract][Full Text] [Related]